Characterizing the impact of sustained sulfadoxine/pyrimethamine use upon the Plasmodium falciparum population in Malawi

As one of the first African countries to switch from chloroquine to sulfadoxine/pyrimethamine (SP) in 1993, and the last to switch from SP to ACT in 2007, Malawi stands out from the rest of Africa in having a significantly prolonged exposure to SP. This study reports the persistence of genetic variants associated with SP and chloroquine resistance within the P. falciparum population in Malawi, despite withdrawal of these anti-malarials from front-line use.

Author: , , , , , , , , , , , , , ,
Publication date: November 2016
Source: Malaria Journal